Corkery, JM; Schifano, F; Ghodse, AH. Phenazepam abuse in the UK: An emerging problem causing serious adverse health problems, including death. Hum. Psychopharmacol. Clin. Exp., 1 May 2012, 27 (3), 254–261. 140 kB. https://doi.org/10.1002/hup.2222
Manchester, KR; Lomas, EC; Waters, L; Dempsey, FC; Maskell, PD. The emergence of new psychoactive substance (NPS) benzodiazepines: A review. Drug Test. Analysis, 1 Jan 2018, 10 (1), 37-53. 713 kB. https://doi.org/10.1002/dta.2211 #2A
EMCDDA. New drugs in Europe, 2011, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Apr 2012. 401 kB.
Bergstrand, MP; Helander, A; Hansson, T; Beck, O. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. Drug Test. Analysis, 1 Apr 2017, 9 (4), 640-645. 522 kB. https://doi.org/10.1002/dta.2003
Lim, WJL; Yap, ATW; Mangudi, M; Koh, H; Tang, ASY; Chan, K. Detection of phenazepam in illicitly manufactured Erimin 5 tablets. Drug Test. Analysis, 1 Feb 2017, 9 (2), 293-305. 1.3 MB. https://doi.org/10.1002/dta.1981
Kavanagh, PV; Power, JD. New psychoactive substances legislation in Ireland – Perspectives from academia. Drug Test. Analysis, 1 Jul 2014, 6 (7-8), 884-891. 1.2 MB. https://doi.org/10.1002/dta.1598
EMCDDA. New drugs in Europe, 2007, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2008. 381 kB. #11
Moosmann, B; Auwärter, V. Designer benzodiazepines: Another class of new psychoactive substances. In Handbook of Experimental Pharmacology; , Springer Berlin Heidelberg, 1 Jan 2018; pp 1–28. 497 kB. https://doi.org/10.1007/164_2018_154 #Phenazepam
· Isomer Design